Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Sanofi India Limited (Previously known as Aventis Pharma Limited) was incorporated in May 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 2012. The ...

News for Sanofi India Ltd. CD&R Acquires 26% Stake in Sanofi Consumer Healthcare India - Rs 2,983 Cr Open Offer Global investment firm CD&R has announced an open offer to acquire a 26% stake ...

CAPA publishes more than 1,000 global News Briefs every week, covering all aspects of the aviation and travel industry. It’s the most comprehensive source of market intelligence in the world, with ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14,230.97 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...

The Matrix collection depicts a complex science fiction story incorporating many philosophical elements. Written and directed by the Wachowskis and produced by Joel Silver.